Published in Mol Cell on July 21, 2006
Modes of p53 regulation. Cell (2009) 9.31
Tumour suppression by p53: a role for the DNA damage response? Nat Rev Cancer (2009) 4.06
Mdm2 regulates p53 mRNA translation through inhibitory interactions with ribosomal protein L26. Mol Cell (2008) 2.46
The transcription-independent mitochondrial p53 program is a major contributor to nutlin-induced apoptosis in tumor cells. Cell Cycle (2009) 2.00
Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry? Mol Cancer Res (2009) 1.87
Ubiquitination and degradation of mutant p53. Mol Cell Biol (2007) 1.77
Cancer-associated mutations in the MDM2 zinc finger domain disrupt ribosomal protein interaction and attenuate MDM2-induced p53 degradation. Mol Cell Biol (2006) 1.76
MDM2 and MDM4: p53 regulators as targets in anticancer therapy. Int J Biochem Cell Biol (2007) 1.59
Ribosomal protein S3: A multi-functional protein that interacts with both p53 and MDM2 through its KH domain. DNA Repair (Amst) (2009) 1.35
The C terminus of p53 binds the N-terminal domain of MDM2. Nat Struct Mol Biol (2010) 1.35
CK1alpha plays a central role in mediating MDM2 control of p53 and E2F-1 protein stability. J Biol Chem (2009) 1.19
Stress-mediated nuclear stabilization of p53 is regulated by ubiquitination and importin-alpha3 binding. Cell Death Differ (2009) 1.12
Molecular mechanism of mutant p53 stabilization: the role of HSP70 and MDM2. PLoS One (2012) 1.11
The MDM2 ubiquitination signal in the DNA-binding domain of p53 forms a docking site for calcium calmodulin kinase superfamily members. Mol Cell Biol (2007) 1.01
A function for the RING finger domain in the allosteric control of MDM2 conformation and activity. J Biol Chem (2009) 1.01
MI-219-zinc combination: a new paradigm in MDM2 inhibitor-based therapy. Oncogene (2010) 1.00
Depletion of guanine nucleotides leads to the Mdm2-dependent proteasomal degradation of nucleostemin. Cancer Res (2009) 1.00
Regulation of MDM2 E3 ligase activity by phosphorylation after DNA damage. Mol Cell Biol (2011) 1.00
HDMX-L is expressed from a functional p53-responsive promoter in the first intron of the HDMX gene and participates in an autoregulatory feedback loop to control p53 activity. J Biol Chem (2010) 1.00
Inhibition of p53 DNA binding function by the MDM2 protein acidic domain. J Biol Chem (2011) 0.99
Pharmacological manipulation of the cell cycle and metabolism to protect normal tissues against conventional anticancer drugs. Oncotarget (2011) 0.98
RFWD3-Mdm2 ubiquitin ligase complex positively regulates p53 stability in response to DNA damage. Proc Natl Acad Sci U S A (2010) 0.98
SCH529074, a small molecule activator of mutant p53, which binds p53 DNA binding domain (DBD), restores growth-suppressive function to mutant p53 and interrupts HDM2-mediated ubiquitination of wild type p53. J Biol Chem (2010) 0.97
MDM2 mediates ubiquitination and degradation of activating transcription factor 3. J Biol Chem (2010) 0.97
A central role for CK1 in catalyzing phosphorylation of the p53 transactivation domain at serine 20 after HHV-6B viral infection. J Biol Chem (2008) 0.96
Casein kinase 1α regulates an MDMX intramolecular interaction to stimulate p53 binding. Mol Cell Biol (2012) 0.94
A small ribosomal subunit (SSU) processome component, the human U3 protein 14A (hUTP14A) binds p53 and promotes p53 degradation. J Biol Chem (2010) 0.92
A role for Numb in p53 stabilization. Genome Biol (2008) 0.91
Insulin receptor tyrosine kinase substrate enhances low levels of MDM2-mediated p53 ubiquitination. PLoS One (2011) 0.91
Enigma negatively regulates p53 through MDM2 and promotes tumor cell survival in mice. J Clin Invest (2010) 0.91
MDM2 promotes proteasomal degradation of p21Waf1 via a conformation change. J Biol Chem (2010) 0.90
MDM2 protein-mediated ubiquitination of numb protein: identification of a second physiological substrate of MDM2 that employs a dual-site docking mechanism. J Biol Chem (2012) 0.90
Docking-dependent ubiquitination of the interferon regulatory factor-1 tumor suppressor protein by the ubiquitin ligase CHIP. J Biol Chem (2010) 0.90
Regulation of the E3 ubiquitin ligase activity of MDM2 by an N-terminal pseudo-substrate motif. J Chem Biol (2009) 0.90
Identification and characterization of two novel isoforms of Pirh2 ubiquitin ligase that negatively regulate p53 independent of RING finger domains. J Biol Chem (2009) 0.90
GNL3L depletion destabilizes MDM2 and induces p53-dependent G2/M arrest. Oncogene (2010) 0.89
MDMX contains an autoinhibitory sequence element. Proc Natl Acad Sci U S A (2013) 0.89
Proteasomal degradation of p53 by human papillomavirus E6 oncoprotein relies on the structural integrity of p53 core domain. PLoS One (2011) 0.89
Disruption of the p53-Mdm2 complex by Nutlin-3 reveals different cancer cell phenotypes. Ethn Dis (2008) 0.88
ZNF668 functions as a tumor suppressor by regulating p53 stability and function in breast cancer. Cancer Res (2011) 0.86
Transcription factor TAFII250 promotes Mdm2-dependent turnover of p53. Oncogene (2007) 0.85
Splicing up mdm2 for cancer proteome diversity. Genes Cancer (2012) 0.85
Regulation of Mutant p53 Protein Expression. Front Oncol (2015) 0.84
On the interaction mechanisms of a p53 peptide and nutlin with the MDM2 and MDMX proteins: a Brownian dynamics study. Cell Cycle (2013) 0.83
Concepts in MDM2 Signaling: Allosteric Regulation and Feedback Loops. Genes Cancer (2012) 0.83
Effects of stability on the biological function of p53. J Biol Chem (2009) 0.82
A novel p53 phosphorylation site within the MDM2 ubiquitination signal: I. phosphorylation at SER269 in vivo is linked to inactivation of p53 function. J Biol Chem (2010) 0.81
The Roles of MDM2 and MDMX Phosphorylation in Stress Signaling to p53. Genes Cancer (2012) 0.81
Controlled access of p53 to the nucleus regulates its proteasomal degradation by MDM2. Mol Pharm (2013) 0.81
Nanosensing protein allostery using a bivalent mouse double minute two (MDM2) assay. Proc Natl Acad Sci U S A (2012) 0.80
C-terminal substitution of MDM2 interacting peptides modulates binding affinity by distinctive mechanisms. PLoS One (2011) 0.79
Exploiting the MDM2-CK1α protein-protein interface to develop novel biologics that induce UBL-kinase-modification and inhibit cell growth. PLoS One (2012) 0.79
A novel p53 phosphorylation site within the MDM2 ubiquitination signal: II. a model in which phosphorylation at SER269 induces a mutant conformation to p53. J Biol Chem (2010) 0.79
The alternative translated MDMX(p60) isoform regulates MDM2 activity. Cell Cycle (2015) 0.79
Nutlin-3 downregulates p53 phosphorylation on serine392 and induces apoptosis in hepatocellular carcinoma cells. BMB Rep (2014) 0.78
Binding of Translationally Controlled Tumour Protein to the N-terminal domain of HDM2 is inhibited by nutlin-3. PLoS One (2012) 0.78
Protein-Protein Interactions Modulate the Docking-Dependent E3-Ubiquitin Ligase Activity of Carboxy-Terminus of Hsc70-Interacting Protein (CHIP). Mol Cell Proteomics (2015) 0.78
The relationship between MDM2 expression and tumor thickness and invasion in primary cutaneous malignant melanoma. J Res Med Sci (2012) 0.77
Identification and characterization of a novel Mdm2 splice variant acutely induced by the chemotherapeutic agents adriamycin and actinomycin D. Cell Cycle (2008) 0.77
Secondary interaction between MDMX and p53 core domain inhibits p53 DNA binding. Proc Natl Acad Sci U S A (2016) 0.76
The E3 ubiquitin protein ligase MDM2 dictates all-trans retinoic acid-induced osteoblastic differentiation of osteosarcoma cells by modulating the degradation of RARα. Oncogene (2016) 0.75
Dual function of MDM2 and MDMX toward the tumor suppressors p53 and RB. Genes Cancer (2016) 0.75
Rearrangement of mitochondrial pyruvate dehydrogenase subunit dihydrolipoamide dehydrogenase protein-protein interactions by the MDM2 ligand nutlin-3. Proteomics (2016) 0.75
JNK2 downregulation promotes tumorigenesis and chemoresistance by decreasing p53 stability in bladder cancer. Oncotarget (2016) 0.75
Regulation of transcriptional activators by DNA-binding domain ubiquitination. Cell Death Differ (2017) 0.75
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Drug discovery and p53. Drug Discov Today (2003) 2.34
DNA-dependent acetylation of p53 by the transcription coactivator p300. J Biol Chem (2002) 1.59
The conformationally flexible S9-S10 linker region in the core domain of p53 contains a novel MDM2 binding site whose mutation increases ubiquitination of p53 in vivo. J Biol Chem (2002) 1.50
The Barrett's antigen anterior gradient-2 silences the p53 transcriptional response to DNA damage. Mol Cell Proteomics (2004) 1.42
The proline repeat domain of p53 binds directly to the transcriptional coactivator p300 and allosterically controls DNA-dependent acetylation of p53. Mol Cell Biol (2003) 1.33
Hypoxia attenuates the p53 response to cellular damage. Oncogene (2003) 1.31
Predictors of the first cardiovascular event in patients with systemic lupus erythematosus - a prospective cohort study. Arthritis Res Ther (2009) 1.29
Mage-A cancer/testis antigens inhibit p53 function by blocking its interaction with chromatin. Cancer Res (2010) 1.27
CK1alpha plays a central role in mediating MDM2 control of p53 and E2F-1 protein stability. J Biol Chem (2009) 1.19
DAPK-1 binding to a linear peptide motif in MAP1B stimulates autophagy and membrane blebbing. J Biol Chem (2008) 1.19
Regulation of the IRF-1 tumour modifier during the response to genotoxic stress involves an ATM-dependent signalling pathway. Oncogene (2002) 1.17
Interferon regulatory factor 1 binding to p300 stimulates DNA-dependent acetylation of p53. Mol Cell Biol (2004) 1.16
Role of Mdm2 acid domain interactions in recognition and ubiquitination of the transcription factor IRF-2. Biochem J (2009) 1.15
The regulation of MDM2 by multisite phosphorylation--opportunities for molecular-based intervention to target tumours? Semin Cancer Biol (2009) 1.13
The regulation of p53 by phosphorylation: a model for how distinct signals integrate into the p53 pathway. Aging (Albany NY) (2009) 1.12
PDK1-dependent activation of atypical PKC leads to degradation of the p21 tumour modifier protein. EMBO J (2002) 1.08
Drug discovery and mutant p53. Trends Cell Biol (2010) 1.04
p63: the phantom of the tumor suppressor. Cell Cycle (2007) 1.04
The MDM2 ubiquitination signal in the DNA-binding domain of p53 forms a docking site for calcium calmodulin kinase superfamily members. Mol Cell Biol (2007) 1.01
A function for the RING finger domain in the allosteric control of MDM2 conformation and activity. J Biol Chem (2009) 1.01
How phosphorylation controls p53. Cell Cycle (2011) 0.99
Death-associated protein kinase (DAPK) and signal transduction: additional roles beyond cell death. FEBS J (2009) 0.97
A central role for CK1 in catalyzing phosphorylation of the p53 transactivation domain at serine 20 after HHV-6B viral infection. J Biol Chem (2008) 0.96
The emergence of the conserved AAA+ ATPases Pontin and Reptin on the signaling landscape. Sci Signal (2013) 0.94
Cooperative regulation of the interferon regulatory factor-1 tumor suppressor protein by core components of the molecular chaperone machinery. J Biol Chem (2009) 0.91
MDM2 protein-mediated ubiquitination of numb protein: identification of a second physiological substrate of MDM2 that employs a dual-site docking mechanism. J Biol Chem (2012) 0.90
Regulation of the E3 ubiquitin ligase activity of MDM2 by an N-terminal pseudo-substrate motif. J Chem Biol (2009) 0.90
Docking-dependent ubiquitination of the interferon regulatory factor-1 tumor suppressor protein by the ubiquitin ligase CHIP. J Biol Chem (2010) 0.90
Anterior Gradient-3: a novel biomarker for ovarian cancer that mediates cisplatin resistance in xenograft models. J Immunol Methods (2012) 0.90
Activation of the DNA-binding ability of latent p53 protein by protein kinase C is abolished by protein kinase CK2. Biochem J (2004) 0.90
A divergent substrate-binding loop within the pro-oncogenic protein anterior gradient-2 forms a docking site for Reptin. J Mol Biol (2010) 0.89
On the mechanism of sequence-specific DNA-dependent acetylation of p53: the acetylation motif is exposed upon DNA binding. J Mol Biol (2005) 0.89
The calcium-binding domain of the stress protein SEP53 is required for survival in response to deoxycholic acid-mediated injury. FEBS J (2006) 0.89
Destabilizing missense mutations in the tumour suppressor protein p53 enhance its ubiquitination in vitro and in vivo. Biochem J (2006) 0.89
p21(WAF1) is component of a positive feedback loop that maintains the p53 transcriptional program. Cell Cycle (2011) 0.89
DeltaNp63 transcriptionally regulates ATM to control p53 Serine-15 phosphorylation. Mol Cancer (2010) 0.88
Chemical states of the N-terminal "lid" of MDM2 regulate p53 binding: simulations reveal complexities of modulation. Cell Cycle (2011) 0.87
Docking-dependent regulation of the Rb tumor suppressor protein by Cdk4. Mol Cell Biol (2004) 0.87
Role of the IRF-1 enhancer domain in signalling polyubiquitination and degradation. Cell Signal (2009) 0.87
Identification of an AKT-dependent signalling pathway that mediates tamoxifen-dependent induction of the pro-metastatic protein anterior gradient-2. Cancer Lett (2013) 0.87
The role of modelling in identifying drug targets for diseases of the cell cycle. J R Soc Interface (2006) 0.87
Age- and sex-specific reference values of a test of neck muscle endurance. J Manipulative Physiol Ther (2007) 0.86
Expansion of protein interaction maps by phage peptide display using MDM2 as a prototypical conformationally flexible target protein. J Mol Biol (2004) 0.86
ATP stimulates MDM2-mediated inhibition of the DNA-binding function of E2F1. FEBS J (2008) 0.85
Chemical genetics approach to identify peptide ligands that selectively stimulate DAPK-1 kinase activity. Biochemistry (2007) 0.85
Ischemic arterial events and atherosclerosis in patients with systemic sclerosis: a population-based case-control study. Arthritis Res Ther (2013) 0.85
Identification of two reactive cysteine residues in the tumor suppressor protein p53 using top-down FTICR mass spectrometry. J Am Soc Mass Spectrom (2011) 0.85
CK2-site phosphorylation of p53 is induced in DeltaNp63 expressing basal stem cells in UVB irradiated human skin. Cell Cycle (2006) 0.84
The effects of phosphomimetic lid mutation on the thermostability of the N-terminal domain of MDM2. J Mol Biol (2010) 0.84
The N-terminal interferon-binding domain (IBiD) homology domain of p300 binds to peptides with homology to the p53 transactivation domain. J Biol Chem (2004) 0.84
A multiprotein binding interface in an intrinsically disordered region of the tumor suppressor protein interferon regulatory factor-1. J Biol Chem (2011) 0.84
The alternative splice variant of DAPK-1, s-DAPK-1, induces proteasome-independent DAPK-1 destabilization. Mol Cell Biochem (2009) 0.84
DNA-binding regulates site-specific ubiquitination of IRF-1. Biochem J (2013) 0.83
Evaluating DAPK as a therapeutic target. Apoptosis (2014) 0.83
Microarray-formatted clinical biomarker assay development using peptide aptamers to anterior gradient-2. Biochemistry (2007) 0.83
Signaling to p53: the use of phospho-specific antibodies to probe for in vivo kinase activation. Methods Mol Biol (2003) 0.82
A novel repressor domain is required for maximal growth inhibition by the IRF-1 tumor suppressor. J Biol Chem (2006) 0.81
Tuberous sclerosis-2 (TSC2) regulates the stability of death-associated protein kinase-1 (DAPK) through a lysosome-dependent degradation pathway. FEBS J (2010) 0.81
A novel p53 phosphorylation site within the MDM2 ubiquitination signal: I. phosphorylation at SER269 in vivo is linked to inactivation of p53 function. J Biol Chem (2010) 0.81
Identification of a second Nutlin-3 responsive interaction site in the N-terminal domain of MDM2 using hydrogen/deuterium exchange mass spectrometry. Proteomics (2013) 0.80
Nanosensing protein allostery using a bivalent mouse double minute two (MDM2) assay. Proc Natl Acad Sci U S A (2012) 0.80
Intrasteric regulation of MDM2. Trends Biochem Sci (2003) 0.80
Exploiting the MDM2-CK1α protein-protein interface to develop novel biologics that induce UBL-kinase-modification and inhibit cell growth. PLoS One (2012) 0.79
A novel p53 phosphorylation site within the MDM2 ubiquitination signal: II. a model in which phosphorylation at SER269 induces a mutant conformation to p53. J Biol Chem (2010) 0.79
The molecular dynamics of MDM2. Cell Cycle (2010) 0.79
Engineering a synthetic cell panel to identify signalling components reprogrammed by the cell growth regulator anterior gradient-2. Mol Biosyst (2014) 0.79
Multienzyme assembly of a p53 transcription complex. Nat Struct Mol Biol (2007) 0.78
Novel insights into DAPK autophagic signalling using peptide aptamer combinatorial protein-interaction screens. Autophagy (2008) 0.78
Intracellular activation of interferon regulatory factor-1 by nanobodies to the multifunctional (Mf1) domain. J Biol Chem (2010) 0.78
Human herpesvirus-6B protein U19 contains a p53 BOX I homology motif for HDM2 binding and p53 stabilization. Virology (2013) 0.78
The regulation of CHK2 in human cancer. Oncogene (2004) 0.77
Development of a fluorescent monoclonal antibody-based assay to measure the allosteric effects of synthetic peptides on self-oligomerization of AGR2 protein. Protein Sci (2013) 0.77
Use of oesophageal stress response proteins as potential biomarkers in the screening for Barrett's oesophagus. Eur J Gastroenterol Hepatol (2008) 0.77
Quantitative proteomic profiling of pleomorphic human sarcoma identifies CLIC1 as a dominant pro-oncogenic receptor expressed in diverse sarcoma types. J Proteome Res (2014) 0.77
A Casein kinase 1/Checkpoint kinase 1 pyrazolo-pyridine protein kinase inhibitor as novel activator of the p53 pathway. Bioorg Med Chem Lett (2013) 0.76
Protein kinases coordinately regulate the p53: Delta Np63 alpha axis after DNA damage. Cell Cycle (2008) 0.75
Erratum: CHIP-dependent regulation of the actin cytoskeleton is linked to neuronal cell membrane integrity. iScience (2022) 0.75